The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Bayer Schering Pharma; Ipsen; Merck Serono; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer Schering Pharma; Eisai; Ipsen; Merck Serono; Prestizia
Research Funding - Merck Serono (Inst)
Travel, Accommodations, Expenses - Bayer Schering Pharma; Merck Serono; Roche/Genentech; Sanofi/Aventis
PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.
 
Valerie Boige
No Relationships to Disclose
 
Jean-Pierre Pignon
No Relationships to Disclose
 
Mathilde Wagner
Consulting or Advisory Role - Canon Medical System
 
Eric Dupont Bierre
No Relationships to Disclose
 
Samuel Le Sourd
No Relationships to Disclose
 
Franck Audemar
No Relationships to Disclose
 
Ayhan Ulusakarya
No Relationships to Disclose
 
Veronique Guerin-Meyer
No Relationships to Disclose
 
Veronica Pezzella
No Relationships to Disclose
 
Maximiliano Gelli
No Relationships to Disclose
 
Diane Goere
No Relationships to Disclose
 
Julien Taieb
Consulting or Advisory Role - Amgen; Baxalta; Celgene; Lilly; Merck KGaA; MSD; Roche; SERVIER; Sirtex Medical
Speakers' Bureau - Amgen; Baxalta; Lilly; Merck; MSD; Roche/Genentech; Sanofi; SERVIER